Clinical Trial Search

Primary: Fold-Change in Epidermal Thickness of Lesional Skin — 1.15; 1.5; 1.18; -1 fold-change

Primary: Number of Allergen-induced Eosinophils in the Skin — 11.95; 71.15 cells/mm2

Primary: Provider-diagnosed Atopic Dermatitis — 217.7; 268.5 Participants with imputed values — p=0.019

Primary: Prescription Rates for Atopic Dermatitis Related Treatments: Emollients and Soap Substitutes — 76095 Participants

Primary: Percentage Change in SCORAD — -18.8; -11.7 percentage change

Primary: Number of Patients Achieving an Improvement (Decrease) in IGA (Investigator Global Assessment) by Two or More Points — 2 participants

Primary: SCORAD Change Score — 33.34 Change Score

Primary: Change From Baseline in the m-EASI (Eczema Area Severity Index) Score. — 5.04; 4.77 units of a 0-12 scale — p=<0.05

Primary: Proportion of SCORAD-50 Response at Week 16. — 5; 3 Participants

Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 — 0 Participants

Primary: Proportion of Patients Achieving an Investigator's Global Assessment (IGA) of 0 (Clear) or 1 (Almost Clear) and a Decrease of at Least 2 Points in IGA at Week 8. — 0.12…

Primary: Severity Scoring of Atopic Dermatitis (SCORAD) Amongst Subjects With Moderate Atopic Dermatitis — -12.2; 9.3; -17.5 units on a scale — p=<0.05

Primary: Change From Baseline to Day 15 in Modified Local SCORing Atopic Dermatitis (SCORAD) — -2.30; -1.75 Scores on a scale — p=0.276

Primary: Percentage of Participants Who Had at Least a 2-grade Reduction From Baseline at Week 6 in the Investigator Global Assessment (IGA) Scale and Had an IGA at Week 6 That…

Primary: Achievement of EASI-50 — 38; 27; 25; 23 Participants

Primary: Change in Itch Intensity as Measured by a Change in Visual Analog Scale (VAS) Score — 0.8; -5.0 centimeters

Primary: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) — 4; 7 Participants

Primary: Skin Barrier Strengthening Effect by Measurement of Trans Epidermal Water Loss (TEWL) Before and After Induction of Skin Irritation — 19.790; 24.680; 29.648; 28.646 TEWL…

Primary: Incidence of Success Based on the Investigator's Global Evaluation at the End of Treatment — 104; 121; 67 participants

Primary: Percent Change in EASI From Baseline at Day 29 — -47.37; -42.10 percent change

Primary: Percent Change From Baseline (PCFB) in Eczema Area and Severity Index (EASI) Score at Week 12 in Group 1 — -66.11; -32.81 Percent Change

Primary: Percentage Change From Baseline in the Eczema Area and Severity Index (EASI) Score at Week 12. — -10.98; -25.99; -31.57 percent change — p=0.1308

Primary: Change in Eczema Area Severity Index (EASI) Score From Baseline (Week 1) to Week 16. — 26.4 Scores on a scale.

Primary: Change From Baseline in Three Item Severity Score — -2.6; -3.6 units on a scale

Primary: Incidence of Success Based on the Investigator's Global Evaluation at the End of Treatment — 123; 130; 86 participants

Primary: Insulin Sensitivity Difference Between Patients With Atopic Dermatitis and Controls — 9.8; 9.2 mg glucose/kg body mass/minute

Primary: Percent Change in CD4+ T Effector Cells Expressing IL4 in Dupilumab-treated Subjects at Week 12 vs Week 0 — 68.4; 100.0 Percent change

Primary: Proportion of Subjects Who Achieve ≥75% Overall Improvement in Eczema Area and Severity Index (EASI) Score From Baseline to Week 16. — 9.8; 18.1; 12.5; 15.1 percentage…

Primary: Seroprotection, Non-Atopic Dermatitis (AD), Intradermal vs. Moderate to Severe Atopic Dermatitis, Intradermal - Influenza B — 34.4; 22.5 percentage of participants…

Primary: Proportion of Patients Achieving an Investigators Global Assessment (IGA) of 0 (Clear) or 1 (Almost Clear) and a Decrease of at Least 2 Points in IGA in Treated…